Drug intelligence / Profile preview

bevacizumab + ketorolac

Development stage: Preclinical
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravitreal, Topical

Overview

A combination therapy consisting of intravitreal bevacizumab injections and topical ketorolac eye drops. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), while ketorolac is a non-steroidal anti-inflammatory drug (NSAID). This combination has been studied for the treatment of diabetic macular edema (DME), with some studies showing that topical ketorolac can enhance and sustain the efficacy of intravitreal bevacizumab, while others show no significant additive benefit.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + ketorolac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + ketorolac.

Explore the full profile